Janssen has announced that the National Institute for Health and Clinical Excellence (NICE), has recommended Stelara® (ustekinumab) in its Final Appraisal Determination (FAD)1 as a treatment option for patients with active psoriatic arthritis, when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
According to the FAD, ustekinumab is recommended as an option, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults only when:
- treatment with tumour necrosis factor (TNF) alpha inhibitors is contraindicated but would otherwise be considered or
- the person has had treatment with 1 or more TNF-alpha inhibitors.
